I anticipate a price correction of approximately 10%, bringing the stock price down to around $18.80. Despite this expected short-term decline, my long-term outlook remains highly positive. The company continues to be a strong profit generator, with revenue growing at an impressive pace. Its newly launched products have been well-received, and there are numerous positive indicators for future growth on the horizon.
Returning to the anticipated 10% correction, it’s worth noting that following the Q2 report, the stock experienced a significant surge, breaking away from its established base trend. This is not an unusual occurrence; similar deviations have been observed in the past. I have highlighted these patterns with markers. In each case, after the price left the base trend, a consolidation phase followed, during which the stock corrected back to the Fibonacci 61.8% retracement level. Historically, all major upward movements have been followed by a retracement to this level.
I expect a similar scenario to play out in the coming weeks, with the price declining to around $18.80. At this point, I plan to purchase a substantial number of shares. Should the price briefly touch the base trendline, this would represent an exceptional buying opportunity—what I would consider a rare gift for long-term investors.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.